Millennium Management’s Ligand Pharmaceuticals LGND Stock Holding History

Millennium Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,577	Closed	-$271K	–	6131
2025 Q1	$271K	Buy	+2,577	New	+$291K	﹤0.01%	5150
2024 Q2	–	Sell	-36,810	Closed	-$2.69M	–	6261
2024 Q1	$2.69M	Buy	36,810 +20,600	+127%	+$1.52M	﹤0.01%	3471
2023 Q4	$1.16M	Sell	16,210 -9,676	-37%	-$571K	﹤0.01%	4041
2023 Q3	$1.55M	Buy	+25,886	New	+$1.7M	﹤0.01%	3807
2023 Q2	–	Sell	-41,996	Closed	-$3.09M	–	6439
2023 Q1	$3.09M	Sell	41,996 -167,611	-80%	-$11.9M	﹤0.01%	3024
2022 Q4	$14M	Sell	209,607 -56,839	-21%	-$3.7M	0.01%	1779
2022 Q3	$14.3M	Buy	266,446 +139,152	+109%	+$8.18M	0.01%	1701
2022 Q2	$7.08M	Sell	127,294 -82,704	-39%	-$4.69M	﹤0.01%	2440
2022 Q1	$14.7M	Sell	209,998 -1,989	-0.9%	-$144K	0.01%	1706
2021 Q4	$20.4M	Buy	211,987 +68,119	+47%	+$6.29M	0.01%	1417
2021 Q3	$12.5M	Sell	143,868 -163,639	-53%	-$12.7M	0.01%	1786
2021 Q2	$25.2M	Buy	307,507 +79,806	+35%	+$6.64M	0.02%	1016
2021 Q1	$21.7M	Buy	227,701 +207,301	+1,016%	+$19.6M	0.02%	1023
2020 Q4	$1.27M	Sell	20,400 -29,296	-59%	-$1.67M	﹤0.01%	3575
2020 Q3	$2.96K	Sell	49,696 -60,638	-55%	-$4.14M	﹤0.01%	2292
2020 Q2	$7.7M	Sell	110,334 -108,047	-49%	-$6.85M	0.01%	1398
2020 Q1	$9.91M	Buy	218,381 +183,731	+530%	+$10.4M	0.02%	861
2019 Q4	$2.25M	Buy	34,650 +4,536	+15%	+$303K	﹤0.01%	2545
2019 Q3	$1.87M	Sell	30,114 -3,749	-11%	-$235K	﹤0.01%	2490
2019 Q2	$2.41M	Buy	33,863 +20,834	+160%	+$1.53M	﹤0.01%	2288
2019 Q1	$1.02M	Sell	13,029 -863,743	-99%	-$65.4M	﹤0.01%	2852
2018 Q4	$74.2M	Buy	876,772 +722,618	+469%	+$77M	0.12%	215
2018 Q3	$26.4M	Buy	+154,154	New	+$23.2M	0.03%	692
2018 Q1	–	Sell	-5,540	Closed	-$473K	–	3888
2017 Q4	$473K	Buy	+5,540	New	+$480K	﹤0.01%	3117
2017 Q3	–	Sell	-12,252	Closed	-$928K	–	3704
2017 Q2	$928K	Buy	+12,252	New	+$857K	﹤0.01%	2480
2017 Q1	–	Sell	-3,610	Closed	-$229K	–	3681
2016 Q4	$229K	Buy	+3,610	New	+$228K	﹤0.01%	3029
2015 Q4	–	Sell	-6,138	Closed	-$328K	–	3612
2015 Q3	$328K	Sell	6,138 -28,538	-82%	-$1.73M	﹤0.01%	2869
2015 Q2	$2.18M	Sell	34,676 -49,570	-59%	-$2.7M	﹤0.01%	1859
2015 Q1	$4.05M	Sell	84,246 -161,265	-66%	-$6.18M	0.01%	1529
2014 Q4	$8.15M	Sell	245,511 -92,374	-27%	-$3M	0.02%	1114
2014 Q3	$9.9M	Buy	337,885 +248,776	+279%	+$8.26M	0.03%	872
2014 Q2	$3.46M	Buy	89,109 +29,078	+48%	+$1.18M	0.01%	1431
2014 Q1	$2.52M	Buy	+60,031	New	+$2.5M	0.01%	1613
2013 Q4	–	Sell	-120,598	Closed	-$3.26M	–	3617
2013 Q3	$3.26M	Buy	120,598 +108,904	+931%	+$3.06M	0.01%	1374
2013 Q2	$273K	Buy	+11,694	New	+$210K	﹤0.01%	2617

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's LGND Position: Q2 2025 in Review

Millennium Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 2,577 shares — an estimated $271K sold.

Millennium Management first reported a position in LGND in Q2 2013 and held it in 35 quarters. The position peaked at $74.2M in Q4 2018. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

Millennium Management reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Millennium Management sold 2,577 Ligand Pharmaceuticals shares in Q2 2025, an estimated $271K.
Millennium Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 35 quarters.
Millennium Management's Ligand Pharmaceuticals position peaked at $74.2M in Q4 2018.
271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.